STOCK TITAN
  1. Home
  2. Financials
  3. QTZM

Quantumzyme Ord Shs Financials

QTZM
Source SEC Filings (10-K/10-Q) Updated Jan 31, 2026 Currency USD FYE July

This page shows Quantumzyme Ord Shs (QTZM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI QTZM FY2025

Recent filings show a liability-heavy shell as cash and total assets nearly disappeared while obligations kept rising.

In FY2025, total assets were just $184 against total liabilities of $491K, showing an obligation structure far larger than the asset base. The imbalance worsened from the prior year, when assets were $10K and liabilities were $353K; with current assets equal to cash, the 0.0004 current ratio implies almost no short-term liquidity buffer.

The share count rose from 34.8M to 39.0M over the same span. Yet cash fell from $5K to $184, so a larger equity base did not coincide with balance-sheet repair. Current assets matching cash also suggests little working capital beyond the smallest liquid resource.

Some figures from recent filings were inconsistent and were omitted from this summary.

Generated by Rhea from SEC filings [ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity Cash Flow Returns 17 / 100
Financial Profile 17/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Quantumzyme Ord Shs's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage
100

Quantumzyme Ord Shs carries a low D/E ratio of -1.00, meaning only $-1.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity
0

Quantumzyme Ord Shs's current ratio of 0.00 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$0

Quantumzyme Ord Shs generated $0 in revenue in fiscal year 2025.

EBITDA
N/A
Net Income
N/A
EPS (Diluted)
$-0.01
YoY+0.0%

Quantumzyme Ord Shs earned $-0.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow
N/A
Cash & Debt
$184
YoY-96.4%

Quantumzyme Ord Shs held $184 in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
39M
YoY+12.0%

Quantumzyme Ord Shs had 39M shares outstanding in fiscal year 2025. This represents an increase of 12.0% from the prior year.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
N/A

Capital Allocation

R&D Spending
N/A
Share Buybacks
N/A
Capital Expenditures
N/A

QTZM Income Statement

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Revenue $0 $0 N/A $0 $0 $0 N/A $0
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses N/A N/A N/A N/A $3K+111.5% $2K N/A $8K
Operating Income N/A N/A N/A N/A -$25K+59.7% -$61K N/A N/A
Interest Expense N/A N/A N/A N/A $5K+14.9% $5K N/A $4K
Income Tax $0 $0 N/A $0 $0 $0 N/A $0
Net Income N/A N/A N/A N/A -$30K+54.5% -$66K N/A -$64K
EPS (Diluted) $-0.12 $0.00 N/A N/A $0.00 $0.00 N/A N/A

QTZM Balance Sheet

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Total Assets $59-67.9% $184-68.5% $5840.0% $584 N/A N/A $10K N/A
Current Assets $59-67.9% $184-68.5% $5840.0% $584 N/A N/A $10K N/A
Cash & Equivalents $59-67.9% $184-68.5% $5840.0% $584-66.7% $2K-65.4% $5K $0 $0
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A N/A
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $418K-14.7% $491K+11.2% $441K+9.5% $403K N/A N/A $293K N/A
Current Liabilities $418K-14.7% $491K+11.2% $441K+9.5% $403K N/A N/A $293K N/A
Long-Term Debt N/A N/A N/A N/A N/A N/A N/A N/A
Total Equity -$418K+14.7% -$491K-11.3% -$441K-9.5% -$403K-7.9% -$373K-8.7% -$343K-21.2% -$283K-105.9% $4.8M
Retained Earnings -$10.0M-76.1% -$5.7M-0.9% -$5.6M-0.7% -$5.6M N/A N/A -$5.4M N/A

QTZM Cash Flow Statement

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Operating Cash Flow N/A N/A N/A N/A -$15K+58.6% -$35K-160.6% -$13K N/A
Capital Expenditures N/A N/A N/A N/A N/A N/A N/A N/A
Free Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Investing Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Financing Cash Flow N/A N/A N/A N/A $11K-72.1% $40K+198.3% $13K N/A
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

QTZM Financial Ratios

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A N/A N/A
Return on Equity N/A N/A N/A N/A N/A N/A N/A -1.3%
Return on Assets N/A N/A N/A N/A N/A N/A N/A N/A
Current Ratio 0.000.0 0.000.0 0.000.0 0.00 N/A N/A 0.03 N/A
Debt-to-Equity -1.000.0 -1.000.0 -1.000.0 -1.00 N/A N/A -1.04 N/A
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Note: Shareholder equity is negative (-$491K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

Quantumzyme Ord Shs (QTZM) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Quantumzyme Ord Shs (QTZM) reported diluted earnings per share of $-0.01 for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Quantumzyme Ord Shs (QTZM) had $184 in total assets as of fiscal year 2025, including both current and long-term assets.

Quantumzyme Ord Shs (QTZM) had 39M shares outstanding as of fiscal year 2025.

Quantumzyme Ord Shs (QTZM) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Quantumzyme Ord Shs (QTZM) had a debt-to-equity ratio of -1.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Quantumzyme Ord Shs (QTZM) has negative shareholder equity of -$491K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Quantumzyme Ord Shs (QTZM) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.

Back to top